Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories total Company Consolidated Net Sales — Worldwide Revenue ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2025
44,328
Period ended Dec 31, 2025
Change on a year earlier
+5.7%
41,950 in FY2024
History
11 years
Since FY2015
Sources
11
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Company Consolidated Net Sales — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 44,328 | +5.7% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 41,950 | +4.6% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 40,109 | -8.1% | SEC Filing (0001628280-24-002009) ↗ |
| FY2022 | Dec 31, 2022 | 43,653 | +1.3% | SEC Filing (0001628280-23-001516) ↗ |
| FY2021 | Dec 31, 2021 | 43,075 | +24.5% | SEC Filing (0001104659-22-007648) ↗ |
| FY2020 | Dec 31, 2020 | 34,608 | +8.5% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 31,904 | +325.7% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 7,495 | +33.5% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 5,616 | -73.1% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 20,853 | +2.2% | SEC Filing (0001104659-17-003920) ↗ |
| FY2015 | Dec 31, 2015 | 20,405 | – | SEC Filing (0001104659-16-091861) ↗ |
Breakdown
What makes up total company consolidated net sales — worldwide revenue ($m)
- Total Company Consolidated Net Sales — Organic / Comparable Sales Growth (%)5.5% · FY2025
- Total Company Consolidated Net Sales — Reported Sales Growth (%)5.7% · FY2025
- Total Company Consolidated Net Sales — Foreign Exchange Impact on Sales Growth (%)0.2% · FY2025
- Total Company Consolidated Net Sales — U.S. Revenue ($M)17,126 · FY2025
- Total Company Consolidated Net Sales — International Revenue ($M)27,202 · FY2025
- Total Company — Organic Sales Growth Excl. COVID-19 Testing (%)6.7% · FY2025
- Total Company — Annual Volume Growth (%)4.8% · FY2025
- Total Company — Annual Net Selling Price Change (%)0.7% · FY2025
- Total Company — Annual Foreign Exchange Translation Impact (%)0.2% · FY2025
- International Markets Share of Consolidated Net Sales (%)61.0% · FY2025
- Emerging Markets Total Company Sales Growth Excl. FX (%)5.1% · FY2025
- Consolidated Operating Margin Profile (%)18.2% · FY2025
Cite this data
StockData. (2026). Abbott Laboratories Total Company Consolidated Net Sales — Worldwide Revenue ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/tot-co-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.